1Liu LZ, Zhou XD, Qian G, et al. AKT1 amplification regulates cisplatin resistance in human lung cancer ceils through the mammalian target of rapamycin/p70S6K1 pathway [J]. Cancer Res 2007,67 ( 13 ) : 6325-6332.
2Hovelmann S,Beckers TL,Schmidt M. Molecular alterations in apoptotie pathways after PKB/Akt mediated chemoresistance in NCI H460 cells[J]. Br J Cancer,2004,90(12) :2370-2377.
3Chattopadhyay S, Maehado Pinilla R, Manguan Garcia C, et al. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small cell lung cancer[J]. Oncogene, 2006,25 (23) : 3335-3345.
4Iikuta K,Takemura K, Kihara M,et al. Overexpression of constitutive signal transducer and activator of transcription 3 mRNA in cisplatin-resistant human non-small cell lung cancer cells[J]. Oncol Rep, 2005,13(2) :217-222.
5Ivashkiv LB. Jak-STAT signaling pathways in cells of the immune system[J]. Rev Immunogenet, 2000,2 ( 2 ) : 220-230.
6Ning ZQ, Li J, McGuinness M, et al. STAT3 activation is required for Asp ( 816 ) mutant c Kit induced tumorigenicity [J].Oncogene, 2001,20(33) :4528-4536.
7Wu C, Wangpaichitr M, Feun L, et al. Overcoming cisplatin resistance by roTOR inhibitor in lung cancer[J]. Mol Cancer, 2005,4 (1) :25.
8Ohashi R, Takahashi F, Cui R, et al. Interaction between CD44 and hyaluronate induces chemoresistance in non-small cell lung cancer cell[J]. Cancer Lett, 2007,252 (2) : 225-234.
9Ueda K,Kawashima H,Ohtani S,et al. The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells [J]. Cancer Res, 2006, 66 ( 19 ) : 9682-9690.
5Asanuma K, Kobaya shi D, Furuya D, et al. A role of survivin in radioresistance of pancreatic cancer cells. Jpn J Cancer Res, 2002,93 : 1057-1062.
6Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol,1998, 60:619-642.
7Fortugno P, Wall NR, Giodini A. et al. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci, 2002, 115:575-585.
8Notarbartolo M, Cervello M, Poma P, et al. Expression of the IAPs in multidrug resistant tumor cells. Oncol Rep, 2004, 11:133-136.
9Olie RA, Simoes-Wust AP, Baumann B, et al. A novel antisense oligonueleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res, 2000, 60 :2805 -2809.
10Wang L, Zhang GM, Feng ZH. Down-regulation of survivin expression reversed multidrug resistance in adriamycin-resistant HL60/ADR cell line. Acta Pharmacol Sin, 2003, 24:1235-1240.
2Sibanda BL, Chirgadze DY, Blundell TL. Crystal structure of DNA- PKcs reveals a large open-ring cradle comprised of HEAT repeats. Nature,2010,463 : 118-121.
3Cho BC,Kim JH,Soo RA,et al. The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancer. Yonsei Med J,2010,51:1-8.
4Yang CT, Hung JY, Lai CL, et al. Gefitinib as first-line therapy for advanced or metastatic non-small cell lung cancer patients in southern Taiwan. Kaohsiung J Med Sci ,2010,26 : 1-7.
5Demedts IK, Vermaelen KY, van Meerbeeck JP. Treatment of extensive-stage small cell lung carcinoma:current status and future prospects. Eur Respir J,2010,35:202-215.
6Shao CJ,Fu J, Shi HL, et al. Activities of DNA-PK and Ku86, but not Ku70, may predict sensitivity to cisplatin in human gliomas. J Neurooncol, 2008,89:27-35.
7Komuro Y, Watanabe T, Hosoi Y, et al. The expression pattern of Ku correlates with tumor radiosensitivity and disease free survival in patients with rectal carcinoma. Cancer,2002,95 : 1199-1205.
8Tseng RC, Hsieh FJ, Shih CM,et al. Lung cancer susceptibility and prognosis associated with polymorphisms in the nonhomologous end- joining pathway genes: a multiple genotype-phenotype study. Cancer,2009,115:2939-2948.
9Kuribayashi T, Ohara M, Sora S, et al. Scriptaid, a novel histone deacetylase inhibitor, enhances the response of human tumor cells to radiation. Int J Mol Med,2010,25:25-29.
10Deriano L, Stracker TH, Baker A, et al. Roles for NBSI in alternative nonhomologous end-joining of V ( D ) J recombination intermediates. Mol Cell ,2009,34 : 13-25.
